Background: Fat grafting is widely carried out in breast cancer patients to improve quality in breast reconstruction.
introduction Fat grafting has been carried out in aesthetic surgery worldwide for many years and, more recently, in breast cancer patients to improve the results of breast reconstruction [1] [2] [3] . While numerous published clinical studies have highlighted the strong interest in this procedure for plastic surgery, experimental studies in mice have focused on the role of adipose tissues in cancer development, both in obesity and following fat injection [4] [5] [6] .
In a recent matched-cohort study, our overall results demonstrated no increased risk of local or distant recurrences in breast cancer patients following lipofilling [7] . However, when we focused specifically on those patients presenting either ductal (DIN) or lobular (LIN) intraepithelial neoplasia, we observed a statistically significant increased risk of local events (LEs) in the group who had undergone lipofilling. Though, because of the small sample size in this subgroup, no definitive conclusions could be drawn from the results. Thus, to verify our preliminary observations we set up a new matched-cohort study, limited to patients with intraepithelial lesions and including a larger number of patients with a longer oncologic follow-up.
method study population
We used the European Institute of Oncology (IEO) Breast Cancer Database to identify all the women who were operated on for primary breast cancer at IEO between 1997 and 2010. We then selected intraepithelial neoplasia patients who had subsequently undergone a lipofilling procedure for reconstructive purposes at our Institute, where there had been no tumour recurrence between the primary and lipofilling interventions. Women with synchronous distant metastases at diagnosis, bilateral or recurrent tumour, and previous breast cancer or breast cancer associated with another cancer were excluded. A total of 59 patients were finally included in the current study, among these 57 DIN and 2 LIN patients ( Table 1) .
All the 59 patients had undergone lipofilling according to the protocol of the Coleman technique, with no additional cell enhancement. The fat tissue was aspirated by a liposuction cannula from the subcutaneous tissue at donor sites. It was then centrifuged and injected into the area where filling was required.
For each of the 59 patients included in our study, we selected, from the same database, two control patients who had undergone surgery for a primary breast epithelial neoplasia but had not undergone a lipofilling year of surgery (within 2 years), type of surgery (quadrantectomy versus mastectomy), histology, ductal intraepithelial neoplasia (DIN), lobular intraepithelial neoplasia (LIN), estrogen receptor (ER), margin status, hormonal therapy and radiotherapy. Moreover, each control patient had a disease-free follow-up period at least as long as the time window between the tumour primary surgery and the lipofilling procedure of the corresponding study patient.
statistical method
The chi-square test was used to assess the differences between the study and the control group in the distribution of prognostic variables. A LE (i.e. local relapse or locoregional relapse) was the primary end point. In the case of no LEs, the observation was censored at the last follow-up visit. The cumulative incidence of LEs was compared across different subgroups according to the main matching criteria by means of the log-rank test. Univariate Cox proportional hazard regression models were used and the results expressed as hazard ratios (HRs) with 95% confidence intervals (CIs). In an exploratory analysis, the effect of lipofilling was investigated in some subgroups. All analyses were carried out with the SAS software (SAS Institute, Cary, NC) and the R software (The R Development Core Team 2004; Free Software Foundation, Boston, MA). Tests were two-sided.
results
The median follow-up period from oncologic surgery for the lipofilling case-group and the control group was 63 and 66 months, respectively, and from baseline 38 and 4 months. Nine LEs were observed (six in the lipofilling and three in the control group). Their characteristics are shown in Table 2 . The 5-year cumulative incidence of LEs in lipofilling and control patients was 18% and 3%, respectively (P = 0.02; Figure 1 ). The median time interval between the first oncologic surgery and LEs was 36 months in the study group and 56 months in the control group. The median time interval between the first lipofilling procedures and LEs was 12 months in the study group. As regards the six LEs found in the lipofilling patients, they included two invasive recurrences, two DIN recurrences and two invasive plus DIN recurrences. In the control group, the three LEs included, two DIN recurrences and one invasive plus DIN recurrence. In addition, there were two contralateral DIN in the lipofilling group, and one contralateral DIN and two contralateral invasive events in the control group.
The 5-year cumulative incidence of LEs in the patients who had been subjected to quadrantectomy was 16.7% in the lipofilling group and 0% in the control group, whereas in the mastectomy patients it was 18.4% and 3.6%, respectively (Figure 2 ). Among the mastectomy patients, there were 26 (44.1%) nipple sparing mastectomy cases in the lipofilling group and 49 (41.5%) in the control group.
Univariate survival analysis of LEs in patients undergone lipofilling (Table 3) showed that Ki-67, kept as a continuous variable, was the only significant factor (P = 0.03). Age at lipofilling, time to baseline from surgery and grade were, however, borderline significant (P = 0.07, 0.09 and 0.06, respectively). In an exploratory subgroup analysis, age <50 years, high-grade neoplasia, Ki-67 ≥ 14 and quadrantectomy procedure were all variables that increased the risk of LEs following lipofilling (P = 0.02, 0.03, <0.01 and 0.04, respectively) ( Figure 2 ). discussion A significant increase of LEs in intraepithelial neoplasia patients has been observed in our controlled study when lipofilling was carried out on patients with intraepithelial Figure 2 . Effect of young age, high grade, Ki-67 or quadrantectomy on the cumulative incidence of local events (LEs). The cumulative incidence of LEs was calculated according to age, grade, Ki-67 and type of surgery, then it was compared in the lipofilling (Lipofilling) and in the control group (no Lipofilling) using the log-rank test. G = Grade.
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Annals of Oncology neoplasia (18% versus 3%; P = 0.02), thus confirming the cancer risk of fat transfer in this sub-group of patients. Although our control group showed a low rate of LEs compared with the usually expected LE rate of, at least, 1% per year [8, 9] , this observation cannot explain the statistical difference between our two groups. The local recurrence rate in the control group may be due to our chosen selection criteria, namely matching the controls according to the interval of time without recurrences between the primary surgery and the date of lipofilling in the study group. This selection protocol likely reduces the expected LE rate in the controls and highlights the excess of LEs in the lipofilling group (18%).
In a very exploratory subgroup analysis, age <50 years, highgrade neoplasia, Ki-67 ≥14 and quadrantectomy increased the risk of LEs in patients who had had a fat transfer procedure. The higher rate of LEs in the quadrantectomy subgroup might be explained by the increased risk of cancer cells being left behind in the conserved breast tissue.
The margin status after quadrantectomy is not perfectly matched between the lipofilling and control groups (Table 1) . However, despite two cases of positive margins in the lipofilling group and one in the control group, none of them developed an LE during the course of the study ( Table 2) .
It was not possible to carry out a multivariate analysis on the results of the lipofilling group (Table 3) because of the small number of events. Ki-67 was the only statistically significant factor. Three other factors were borderline significant (age at lipofilling, time to baseline from surgery and grading). We found an increased LE risk in the high-grade intraepithelial neoplasia patients, consistent with the results of Bijker et al.'s study [9] . Moreover, in our study, Ki-67≥ 14% is also a strong significant LE risk as confirmed by others [8] . Our univariate analysis also suggests that the risk of LEs is higher in patients who have a shorter period of time between oncologic surgery and lipofilling. Indeed, no LE was found when lipofilling was carried out >3 years after oncologic surgery. Conversely, Perrot et al. have reported a late local recurrence of osteosarcoma, which occurred 13 years after the initial cancer treatment and 18 months after a lipofilling procedure [10] .
In our study, we found a total of nine LEs (six in the lipofilling group and nine in the control), but no metastatic event was found despite five of the nine being invasive carcinoma recurrences. Such a result is consistent with the relatively short follow-up period. Finally, it is of interest to note that the number of events in the contralateral breast does not differ between the two groups (2 versus 3, respectively). This may indicate that lipofilling does not have a systemic effect.
Several hypotheses might explain the increased incidence of LEs in the LIN-DIN patients who had undergone lipofilling. Our and other laboratories have recently reported that adipose tissue progenitors can support breast cancer tumour growth [11, 12] and metastases [5] , possibly acting as physicochemical regulators [13] . Thus, if LIN-DIN cells accumulate fewer genetic lesions than invasive breast cancer cells, they may be more receptive to supportive signalling from stromal cells, including adipocytes and other cells derived from adipose tissue progenitors [14, 15] . Alternatively, the LIN-DIN stromal cells might have a unique gene expression signature that is crucial for the survival of LIN-DIN cells [15] . Once reinjected, these autologous stromal cells might break LIN-DIN cell dormancy in some patients. Espina et al. have recently suggested that malignant precursor cells pre-exist in human breast ductal carcinoma in situ and require autophagy for [16] . They also showed that the lysosomotropic inhibitor chloroquine phosphate can suppress the stroma invasion of these cells. Thus, it could be of interest to investigate, in preclinical models of breast cancer, whether chloroquine phosphate can abrogate the supportive effect of adipose progenitors. Moreover, more studies are now needed to better investigate tumour cell dormancy and the tumourpromoting role of angiogenesis, inflammatory factors, inflammatory and immune cells as well as adipose tissue progenitors.
Our study has several limitations, such as a retrospective series of patients, different types of cancer treatments, a relatively small number of patients and follow-ups limited to a median of 5 years after primary surgery. Especially when we carried out the subgroup analysis, the result is only exploratory, and no definite conclusion should be drawn from it. Some of the patients in this study were included in our previous study, so this new study confirms our previous observations concerning the intraepithelial neoplasia patient subgroup with higher number of patients and limited to histology to only intraepithelial neoplasia [7] .
conclusion
Our results raise the question of the safety of lipotransfer in intraepithelial neoplasia. Further studies are urgently required to validate these results as this technique is relatively new and no long-term safety data are available. Matched-cohort studies like this one are also essential to explore the cancer risk in patients treated with cell-enhancement techniques, which may strengthen the effect of progenitor cells and the tumour microenvironments on dormant cancer cells.
Our results indicate that intraepithelial neoplasia patients offered a lipotransfer should be given full information on the current questions concerning the potentially higher risk of local recurrences in young patients with high tumour grade and positive Ki-67.
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